Pliant Therapeutics Inc (NAS:PLRX)
$ 13.4 -0.78 (-5.5%) Market Cap: 808.37 Mil Enterprise Value: 427.69 Mil PE Ratio: 0 PB Ratio: 1.85 GF Score: 34/100

Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 18, 2022 / 02:00PM GMT
Release Date Price: $4.84 (-1.63%)
Brian Abrahams
RBC Capital Markets - Analyst

Good morning, everyone. I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets. I'm very pleased to have our next presenting company, Pliant Therapeutics, represented by their President and CEO, Bernard Coulie. Bernard, thanks so much for joining us and great to see you in person.

Bernard Coulie
Pliant Therapeutics, Inc. - President & CEO

Thanks for having me, Brian.

Questions & Answers

Brian Abrahams;
RBC Capital Markets - Analyst

So a lot of exciting things going on at Pliant and some data that's imminent and definitely want to get to that. But maybe just first for those who may be a little bit newer to the story, would love to take a step back and hear a little bit about the overall platform and general mechanistic rationale for targeting TGF-beta through integrins, why you selected alpha-v beta-1, alpha-v beta-6 for IPF and PSC. And maybe just a quick refresher on the latest status of where 809 is in development.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot